Dynogen Pharmaceuticals Inc., of Waltham, Mass., was awarded U.S. Patent No. 6,846,823 related to the use of DDP225, formerly known as MCI225, to treat lower urinary tract disorders. The patent covers the use of a class of thieno (2,3-d) pyrimidine derivatives, including DDP225, to treat urinary frequency, urgency, nocturia and enuresis.

Icoria Inc., of Research Triangle Park, N.C., was granted U.S. Patent No. 6,852,484, titled, "Methods for the Identification of Inhibitors of Asparagine Synthase as Antibiotics," covering the discovery of a gene target for fungicide development.

Imcor Pharmaceutical Co., of San Diego, received a notice of allowance for a patent directed to a method of forming stabilized microbubbles using perfluorocarbons and other gases in various membrane-forming materials.

Imugene Ltd., of Sydney, Australia, was granted a U.S. patent for its Receptor Mimic Technology through 2020. The RMT is the platform for Imugene's products for pigs, poultry and cattle, including one of the company's lead products to prevent E. coli post-weaning diarrhea in pigs.